| 1.45 -0.17 (-10.49%) | 08-17 12:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.86 |
1-year : | 1.97 |
| Resists | First : | 1.59 |
Second : | 1.69 |
| Pivot price | 1.57 |
|||
| Supports | First : | 1.44 |
Second : | 1.19 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.56 |
| MA(100) : | 1.63  |
MA(250) : | 1.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53 |
D(3) : | 68.7 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 2.56 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OSTX ] has closed below the lower bollinger band by 4.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ OSTX ] is to continue within current trading range. It is unclear right now based on current values. 41.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.63 - 1.64 | 1.64 - 1.65 |
| Low: | 1.54 - 1.55 | 1.55 - 1.56 |
| Close: | 1.61 - 1.62 | 1.62 - 1.63 |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Fri, 14 Aug 2026
OSTX: Net loss increased to $19.0 million amid rising R&D costs and ongoing liquidity challenges - TradingView
Thu, 13 Aug 2026
OS Therapies Expects 3-Year Survival Data in September - Stock Titan
Fri, 07 Aug 2026
OS Therapies Incorporated (NYSE: OSTX) Stock Price, News & Analysis - Kalkine
Sat, 01 Aug 2026
OS Therapies (NYSEAMERICAN:OSTX) Shares Down 2.6% - Here's What Happened - MarketBeat
Sat, 25 Jul 2026
OS Therapies Incorporated Revenue Breakdown – AMEX:OSTX - TradingView
Mon, 29 Jun 2026
OS Therapies Incorporated(NYSEAM:OSTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|